Having demonstrated that activation of AMPA-type glutamate receptors stimulates FYN → ERK signaling that results in the proliferation of hypoxic Hep3B cells, we next asked whether inhibiting this pathway using the AMPA receptor antagonist GYKI 52466 would have anti-cancer effects in vivo. The gene discussed is FYN; the disease is cancer.